Please note

Due to the recent spike in Covid-19 cases, we are no longer able to entertain walk-in visits to our headquarters or any of our facilities.

Tricefin powder for injection

Dexa Medica

Ingredients in every vial

Ceftriaxone 1000 mg

Each package contains

1 vial of 1 g

Dosage form

Powder for injection

Dosage formPowder for Injection

Flavour

None

W.H.O. classification

J01D
J01D

A.T.C. Level 1

Anatomical Main group

J - Antiinfectives for systemic use
J01D

A.T.C. Level 2

Therapeutic subgroup

J01 - Antibacterials for Systemic Use
J01D

A.T.C. Level 3

Pharmacological subgroup

J01D - Other Beta-Lactam Antibacterials in ATC

Available in

Indonesia
Singapore

Warnings

Alcohol

CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.

Machinery

CAUTIONThis item may not be safe for use while operating heavy machinery. Use with caution and after consultation with your doctor.

Pregnancy

CONSULT YOUR DOCTORSafety of this item for use during pregnancy has not been established. Please consult your doctor.

Lactation

CAUTIONThis item may not be safe for use during lactation. Use with caution and after consultation with your doctor.

Indication

Infections caused by bacteria which are sensitive to ceftriaxone e.g.,:
Lower respiratory tract infections
Skin and skin structure infections
Bone and joint infections
Intra-abdominal infections
Urinary tract infections; meningitis; septicemia
Perioperative surgical prophylaxis infection
Infections in patients with impaired defense mechanisms

Dosage

0 TO 2 WEEKS OLD
20 – 50 mg/kg body weight once daily, not exceed 50 mg/kg body weight. The daily dosage should not exceed 50 mg/kg body weight on account of the immaturity of the infant's enzyme systems.

3 WEEKS TO 12 YEARS OLD
The daily dose is 20 – 80 mg/kg of body weight. For children with body weight ≥ 50 kg usual dosage is the same as adult dosage. Intravenous doses of 50 mg/kg body weight or more should be given by infusion for at least 30 minutes.

12 TO 65 YEARS OLD
Usual dose: 1–2 g once daily (every 24 hours).
In severe infections and in cases in which the pathogens are only moderately sensitive, the daily dosage may be increased to 4 g once daily.

GERIATRIC PATIENTS
The recommended dosages as the dosage for adults. No adjustment dosage is required in geriatric patients.

DURATION OF THERAPY
The duration of therapy varies according to the course of the disease. As with antibiotic therapy in general, administration of ceftriaxone should be continued for a minimum of 48 to 72 hours after the patient has become afebrile or evidence of bacterial eradication has been obtained.

COMBINATION THERAPY
Synergy between ceftriaxone and aminoglycosides has been demonstrated with many Gram-negative bacteria. Although enhanced activity of such combinations is not always predictable, it should be considered in severe, life-threatening infections due to microorganisms such as Pseudomonas aeruginosa. As the two antibiotic agents are incompatible, they must be administered separately at the recommended dosages.

SPECIAL DOSAGE INSTRUCTIONS
— Meningitis:
The treatment of meningitis in infants and children, treatment begins with doses of 100 mg/kg (up to a maximum of 4 g) once daily. As soon as the causative organism has been identified and its sensitivity determined, the dosage can be reduced accordingly.

Treatment courses that have been found effective include:
– Neisseria meningitidis: 4 days
– Haemophylus influenzae: 6 days
– Streptococcus pneumoniae: 7 days

— Gonorrhea:
For the treatment of gonorrhea by penicillinase-producing and non-penicillinase-producing strains), a single intramuscular dose of 250 mg ceftriaxone is recommended.

— Perioperative prophylaxis:
To prevent postoperative infections in contaminated or potentially contaminated surgery, the recommended approach - depending on the risk of infection - is a single dose of 1 to 2 g ceftriaxone administered 30 to 90 minutes prior to surgery.

In colorectal surgery, concurrent treatment of ceftriaxone with or without a 5-nitroimidazole, e.g., ornidazole (administered separately) has proven effective.

IMPAIRED RENAL AND HEPATIC FUNCTION
In patients with impaired renal function, there is no need to reduce the dosage of ceftriaxone provided hepatic function is intact. Only in cases of pre-terminal renal failure (creatinine clearance <10 ml/minute) the ceftriaxone dosage should not exceed 2 g daily. In patients with liver damage, there is no need for the dosage to be reduced provided renal function is intact. In cases of concomitant severe renal and hepatic dysfunction, determine the plasma concentrations of ceftriaxone at regular intervals. Patients undergoing dialysis require no additional supplementary dosing following the dialysis. Plasma concentrations should, however, be monitored, to determine if dosage adjustments are necessary, since in these patients, the elimination rate may be altered.